Status:

COMPLETED

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

Lead Sponsor:

Ascendis Pharma A/S

Conditions:

Growth Hormone Deficiency, Pediatric

Endocrine System Diseases

Eligibility:

All Genders

1-18 years

Phase:

PHASE3

Brief Summary

A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial....

Eligibility Criteria

Inclusion

  • Children who have completed a prior phase 3 TransCon hGH trial
  • Children who have not permanently discontinued study drug in the prior trial
  • Written, signed, informed consent of the parent or legal guardian of the subject and written assent of the subject as required by the IRB/HREC/IEC

Exclusion

  • Poorly-controlled diabetes mellitus (HbA1c ≥ 8.0%) or diabetic complications
  • Evidence of closed epiphyses, defined as bone age \> 14.0 years for females or \> 16.0 years for males
  • Major medical conditions unless approved by Medical Expert
  • Known hypersensitivity to the components of the trial medication
  • Likely to be non-compliant with respect to trial conduct (in regards to the subject and/or the parent/legal guardian/caregiver)
  • Pregnancy
  • Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule

Key Trial Info

Start Date :

December 19 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 21 2023

Estimated Enrollment :

298 Patients enrolled

Trial Details

Trial ID

NCT03344458

Start Date

December 19 2017

End Date

February 21 2023

Last Update

May 8 2024

Active Locations (42)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 11 (42 locations)

1

Ascendis Pharma Investigational Site

Birmingham, Alabama, United States, 35233

2

Ascendis Pharma Investigational Site

Los Angeles, California, United States, 90048

3

Ascendis Pharma Investigational Site

Orange, California, United States, 92868

4

Ascendis Pharma Investigational Site

Sacramento, California, United States, 95821